Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma

Norihito Soga, Koichiro Yamakado, Hideo Gobara, Haruyuki Takaki, Takao Hiraki, Tomomi Yamada, Kiminobu Arima, Kan Takeda, Susumu Kanazawa, Yoshiki Sugimura

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P <0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months. The recurrence-free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications. CONCLUSION Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.

Original languageEnglish
Pages (from-to)790-794
Number of pages5
JournalBJU International
Volume104
Issue number6
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Renal Cell Carcinoma
Neoplasm Metastasis
Lung
Neoplasms
Survival
Survival Rate
Recurrence
Chest Tubes
Pneumothorax
Pneumonia
Safety

Keywords

  • Lung metastasis
  • Percutaneous radiofrequency ablation
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. / Soga, Norihito; Yamakado, Koichiro; Gobara, Hideo; Takaki, Haruyuki; Hiraki, Takao; Yamada, Tomomi; Arima, Kiminobu; Takeda, Kan; Kanazawa, Susumu; Sugimura, Yoshiki.

In: BJU International, Vol. 104, No. 6, 09.2009, p. 790-794.

Research output: Contribution to journalArticle

Soga, Norihito ; Yamakado, Koichiro ; Gobara, Hideo ; Takaki, Haruyuki ; Hiraki, Takao ; Yamada, Tomomi ; Arima, Kiminobu ; Takeda, Kan ; Kanazawa, Susumu ; Sugimura, Yoshiki. / Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. In: BJU International. 2009 ; Vol. 104, No. 6. pp. 790-794.
@article{90b71cc5b7c3437ab74648a57f6fb9a7,
title = "Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma",
abstract = "Objective: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100{\%} vs 90{\%}), 3 years (100{\%} vs 52{\%}) and 5 years (100{\%} vs 52{\%}) (P <0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33{\%}) during the mean follow-up of 25 months. The recurrence-free survival rates were 92{\%} at 1 year, 23{\%} at 3 years and 23{\%} at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7{\%}) and pneumonia (one of 89, 1{\%}) were major complications. CONCLUSION Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.",
keywords = "Lung metastasis, Percutaneous radiofrequency ablation, Renal cell carcinoma",
author = "Norihito Soga and Koichiro Yamakado and Hideo Gobara and Haruyuki Takaki and Takao Hiraki and Tomomi Yamada and Kiminobu Arima and Kan Takeda and Susumu Kanazawa and Yoshiki Sugimura",
year = "2009",
month = "9",
doi = "10.1111/j.1464-410X.2009.08459.x",
language = "English",
volume = "104",
pages = "790--794",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma

AU - Soga, Norihito

AU - Yamakado, Koichiro

AU - Gobara, Hideo

AU - Takaki, Haruyuki

AU - Hiraki, Takao

AU - Yamada, Tomomi

AU - Arima, Kiminobu

AU - Takeda, Kan

AU - Kanazawa, Susumu

AU - Sugimura, Yoshiki

PY - 2009/9

Y1 - 2009/9

N2 - Objective: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P <0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months. The recurrence-free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications. CONCLUSION Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.

AB - Objective: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P <0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months. The recurrence-free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications. CONCLUSION Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.

KW - Lung metastasis

KW - Percutaneous radiofrequency ablation

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=69249140675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249140675&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.08459.x

DO - 10.1111/j.1464-410X.2009.08459.x

M3 - Article

C2 - 19338555

AN - SCOPUS:69249140675

VL - 104

SP - 790

EP - 794

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -